address and and Thank to thank for you we challenges us. Good safe you, afternoon, presented I families all COVID-XX. remain and hope continue as the by that you your healthy joining Matt. all
quarter. performance team’s in the very are operating pleased with our We third
centers increased to as teams procedural business our case in support to as sales pre-COVID levels of outpatient the volume and we clinical activity physicians PAD with and engaged First, returned revenue returned. elective hospitals
growth and commercial Second, to clearance crosser initiatives our expansion we achieved ahead, the of our CTO of for milestones both including And funding FDA strategic operating Tigereye growth our third, next-generation we XXXX. our sustainable our opportunities improve reductions the providing team. model, OpEx through strengthened and key revenue
our structure. third XX% margin revenue quarter, in the the strongest gross goals, delivering past balance met clinical anticipated improving in and a sheet XX% years studies fund During XXXX. we while the with case financial new four through third sequential growth with to launches, key to including We significantly ended the operating cost maintaining a activity quarter our and programs lean capital product increase resources
Avinger in the emerged to tough further developments watchful from remain we pandemic, we better While equipped stronger, year a for has grow. believe COVID-XX leaner and
new sites account front, additional XX fourth report new in in that the an third the quarter. we On the and four launched to quarter sites already have new I’m happy opened
year and Tigereye, are the made and that the interested I Our many CTO-crossing SV of new addition is launch our know Pantheris portfolio. you plans to of in new for Tigereye the brighter promising account our even is product remainder catheter. for image-guided of outlook with now our
performance clinical first, believe launch. following staged launch on launch. and training availability limited to then and clinical to successful We training and initial experienced Lumivascular number to We starting new our learning for including through executed allows a national into highly and initial programs that develop obtain initial same also experience, of program SV: the case cycling works using are best and real-world for to specialists to us the we approach and sales national launch prior clinical setting the expanding our less insights prior with a studies or reps launch in fine-tune our teams, for this It experienced Lumivascular sites capabilities support for Pantheris the commercial sites; device the physicians of users.
was observe challenging I outcomes by cases the patient to able at happy first physicians. we As We personally October, of sites by we patients number very first U.S. CTOs. of patient have encouraged the of successfully Many physician cases on announced pioneering to completed delivered treated in be these in our at Tigereye most with and of performance of all, feedback highly thrilled these outcomes first all these the CLI very were the was experienced and, commercial a had highly three sites. device announcing expanding more launch subject success we the already one approaches, Since crossing sites or using program, invasive amputation. quarter. to of site bypass to this previously of in several our with launch by plan scheduled attempts end for and anticipate to to national availability surgery launch we’ve future launched week January cases, up three XXXX. the fourth possible next first with XX with conventional on additional the Tigereye have Based for failed sites scheduled with
the for of to Tigereye about drive prospects our growth business. excited image-guided We’re CTO-crossing
family Our current have Ocelot market the been for catheters CTO-crossing almost years. in of eight
sales good recent with Ocelot in devices strong we’ve are decline years. these a volumes following, While seen
developed our of again features both refreshed increased which feedback and cycle. the important in small believe the launch that were treatment introduction this physician franchise above development atherectomy Tigereye launch with We were the the utilization the and will knee. our users business catheter input for during CTO-crossing from time, year Pantheris physician vessels, Pantheris last vitalize of of SV, which on customers the our our with of expands below the based of and catheters, next-generation During our XXXX Pantheris new with then
imaging followed across intravascular and to the believe knee. penetrate working high-definition, to Since by to with date devices. next-generation above Tigereye include a in speeds provided elements new OCT five lesions assist the in lesions. our similar the have a sheath Most The our allows and to completed catheters; distal opportunity by Pantheris tip product device CTO exchange vessel; disposable below we of challenging categories. the peripheral of cases of design strengthened as product, New French both Tigereye on deflectable a user-controlled steerability treatment has the compatibility catheter for centimeters one for been we’ve growth it faster our designed of crossing. our with platform same Pantheris Tigereye, treatment vessels Pantheris atherectomy for tip to XXX runs atherectomy rapid Tigereye the drive rotational Pantheris With all following to configuration real-time a imaging, designed within and length
major major LXXX under in will platform, imaging Lightbox in the the is product represents new last console, next development it name the Our with which major Lightbox the improvement third brand Lightbox since our introduced platform XXXX. be advance X in marketed
revolutionary quarter, make During progress on this we redesign. continued to the third
of X software recall, OCT believe interface, adds As X Lightbox system our for next-generation operation The system. more shipping, system. also our through simplified a laser, cath you integration most reduction and approximately Perhaps of customer computing incorporates for solid-state Lightbox platform strategy a reduced and the incorporates with to imaging current an the pounds a and XX service efficient lab state-of-the-art use all, compared This will we radically which transport, ease exciting efficiency. may provide an a user XX% into will comes environment. and Lightbox streamline weight Lightbox advanced proprietary X powerful size the cost-efficient XXX brings improved for of pounds easy
in our adoption, is proprietary Lightbox run reduction testing. to more prospective up technology help get current which complete, into Lightbox. new sooner acquisition X We utilization we image-guided to significant devices the product our the site. anticipated a in is their of on to Lightbox accounts, XX% cadaver support new physician X been believe uptake the ease image-guided to Lightbox account compared evaluation will labs catheters In the the used cost physician laboratory overall. expect process also rate of and once our believe X improve accounts design and Lightbox increase X our prototypes to and Lumivascular experience largely and the provide We short, increased have for accelerate successfully cath will
of verification prototypes receive Based application of Marking the anticipate this XXX(k) submitting initiating X quarter. first of middle to to of CE XXXX. for process We’re for final this testing in half receive launch expect FDA the validation building U.S. and trial successful U.S. we Lightbox for XXXX testing, Lightbox a the half of premarketing the clearance the to first final clearance XXXX. for of completion and on and We in in anticipate in in Europe the hope X
in-stent of anticipate INSIGHT for clinical support or side, the follow-up key efforts, our patient slowed trial programs, and arteries. evaluating for of XXX(k) in received include treatment that be in Pantheris study We ISR has other this the number while of patients indication extremity believe application the U.S. to to The we’ve in advance ISR highly Pantheris to of continued analysis very ISR the our submission first of pandemic compelling some compared data encouraging and XXXX to clinical expand IDE seeing devices including On the from lower past. quarter sufficient completing for a we our the to we data continue the label are atherectomy have a indication. restenosis to be will
peripheral endpoints safety trial SV Our IMAGE-BTK, for a other the designed in of the and primary post-market artery lesions below efficacy clinical study is knee. evaluate treatment Pantheris to
had As new recall, early the year due our first in but COVID-XX this we site paused you initiation might enrolled restrictions. patients study to
half distributor adding the site process of by this and should with believe to the in enrollment week, XXXX. Medical are make products successful for of first distribution market our cases to are anticipated through the also progress to in of We the We’ve restarted we in a Last already process also distribution first We’ve study of first in our be further XXXX. through country the half products continued Supplies. three enrollment our study our in working with announced quarter. launch patient Israel complete the process in registration a Mexico patient sites and relationship in existing the launch COVID-XX, market agreement products. in for the in on we Unless and new an international signed Neopharm able have of we Lumivascular delayed that
return with treatment. unique treatment are to their therapeutic business need best make procedure, physicians a to while new realize the By the turn and them rapid patients approach that Before over decisions the we growth to for our Mark, highlight just vascular potential are products imaging beginning during more disease. want the believe clinical and after both exciting, provide they the of information during our I to our we once I of call and to empowering to real-time we
case through increasing taken our sheet of We’re seeing impact operating sheet to our improve and to our operations structure clinical this and steps data in every our our positive XXXX. renewed day. strengthen business leaner in initiatives activity We’ve the fund balance our approach and balance anticipated with important
and While difficult several past execute financials, years. this approach back and then new in has the been respects, excited time beginning to very I’d any point, year are a to believe I now the Mark? we XXXX of like of I’ll than At better about end at come positioned Q&A. in the to our ask a We the Mark for future. many this year cover
